北陆药业
(300016)
| 流通市值：45.44亿 | | | 总市值：45.49亿 |
| 流通股本：5.81亿 | | | 总股本：5.82亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,058,562,008.63 | 673,330,527.05 | 320,369,738.33 | 1,205,275,821.64 |
| 营业收入 | 1,058,562,008.63 | 673,330,527.05 | 320,369,738.33 | 1,205,275,821.64 |
| 二、营业总成本 | 932,911,671.51 | 588,966,363.56 | 279,988,815.02 | 1,155,065,353.55 |
| 营业成本 | 622,527,017.45 | 378,074,368.94 | 171,336,811.23 | 653,176,771.33 |
| 税金及附加 | 10,815,315.26 | 7,385,905.8 | 3,745,144.95 | 15,464,041.36 |
| 销售费用 | 165,013,696.64 | 115,626,435.38 | 60,907,136.02 | 261,516,764.82 |
| 管理费用 | 76,894,716.56 | 47,007,302.05 | 23,176,042.59 | 92,629,690.14 |
| 研发费用 | 42,146,228.37 | 30,208,244.94 | 15,449,204.98 | 93,390,891.43 |
| 财务费用 | 15,514,697.23 | 10,664,106.45 | 5,374,475.25 | 38,887,194.47 |
| 其中:利息费用 | 9,544,953.75 | 6,793,398.41 | 3,394,425.51 | 39,777,306.72 |
| 其中:利息收入 | 4,574,401.5 | 2,470,750.06 | 1,212,104.13 | 4,288,976.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 223,719.35 | 2,208,188.6 | 2,845,628.86 | 53,436,304.56 |
| 加:投资收益 | 12,281,839.63 | 9,519,347.89 | 5,496,941.93 | 8,067,847.7 |
| 资产处置收益 | 4,078.96 | - | - | -1,229,172.24 |
| 资产减值损失(新) | -5,628,870.91 | -2,315,090.27 | 1,532,821.38 | -9,137,090.82 |
| 信用减值损失(新) | -799,981.01 | 926,511.49 | 999,423.38 | -4,202,488.92 |
| 其他收益 | 8,912,312.45 | 7,075,239.38 | 3,647,508.18 | 13,131,876.71 |
| 四、营业利润 | 140,643,435.59 | 101,778,360.58 | 54,903,247.04 | 110,277,745.08 |
| 加:营业外收入 | 532,448.32 | 113,292.74 | 1,812.2 | 526,452.91 |
| 减:营业外支出 | 1,873,868.41 | 856,414.44 | 206,943.85 | 2,290,603.75 |
| 五、利润总额 | 139,302,015.5 | 101,035,238.88 | 54,698,115.39 | 108,513,594.24 |
| 减:所得税费用 | 17,930,102.76 | 15,863,580.06 | 8,543,731.65 | 19,865,522.23 |
| 六、净利润 | 121,371,912.74 | 85,171,658.82 | 46,154,383.74 | 88,648,072.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 121,371,912.74 | 85,171,658.82 | 46,154,383.74 | 88,648,072.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 113,902,440.6 | 79,752,147.25 | 44,975,808.94 | 92,734,719.39 |
| 少数股东损益 | 7,469,472.14 | 5,419,511.57 | 1,178,574.8 | -4,086,647.38 |
| 扣除非经常损益后的净利润 | 101,211,292.34 | 73,431,354.11 | 39,717,696.41 | 40,057,378.9 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.2 | 0.14 | 0.08 | 0.18 |
| (二)稀释每股收益 | 0.2 | 0.14 | 0.08 | 0.18 |
| 九、综合收益总额 | 121,371,912.74 | 85,171,658.82 | 46,154,383.74 | 88,648,072.01 |
| 归属于母公司股东的综合收益总额 | 113,902,440.6 | 79,752,147.25 | 44,975,808.94 | 92,734,719.39 |
| 归属于少数股东的综合收益总额 | 7,469,472.14 | 5,419,511.57 | 1,178,574.8 | -4,086,647.38 |
| 公告日期 | 2026-10-28 | 2026-08-25 | 2026-04-29 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |